Janney Montgomery Scott LLC Has $1.28 Million Stock Position in Moderna, Inc. $MRNA

Janney Montgomery Scott LLC grew its position in Moderna, Inc. (NASDAQ:MRNA) by 235.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 46,329 shares of the company’s stock after purchasing an additional 32,504 shares during the period. Janney Montgomery Scott LLC’s holdings in Moderna were worth $1,278,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. S Bank Fund Management Ltd acquired a new position in shares of Moderna in the first quarter worth about $25,000. TD Private Client Wealth LLC boosted its holdings in shares of Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after purchasing an additional 743 shares during the period. SVB Wealth LLC acquired a new stake in shares of Moderna during the first quarter worth approximately $28,000. CX Institutional boosted its holdings in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after purchasing an additional 949 shares during the period. Finally, Costello Asset Management INC acquired a new stake in shares of Moderna during the first quarter worth approximately $30,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MRNA has been the subject of several research reports. Leerink Partners decreased their price target on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a report on Friday, August 22nd. Morgan Stanley raised their price target on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday. Citigroup initiated coverage on shares of Moderna in a report on Friday, August 1st. They set a “neutral” rating and a $40.00 price target for the company. Evercore ISI set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Finally, Cowen initiated coverage on shares of Moderna in a research note on Sunday, July 13th. They issued a “hold” rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, Moderna has an average rating of “Hold” and an average target price of $41.81.

Moderna Stock Down 2.5%

NASDAQ MRNA opened at $26.83 on Monday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $59.73. The stock has a market capitalization of $10.48 billion, a PE ratio of -3.56 and a beta of 2.01. The company has a 50 day moving average price of $25.92 and a two-hundred day moving average price of $27.14.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same quarter last year, the firm posted ($3.33) earnings per share. The company’s quarterly revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.